Research programme: B-Raf kinase inhibitors - Pfizer
Alternative Names: PF-04880594; WYE-130600Latest Information Update: 04 Nov 2017
At a glance
- Originator Pfizer
- Class Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 01 Sep 2011 Preclinical development is ongoing in US
- 26 Mar 2009 Early research in Cancer in USA (unspecified route)